A Prescription for Anxiety: An Analysis of Three Brand-Name Drug Companies and Delayed Generic Drug Market Entry
Barbara J. Williams
This article will examine the statutory framework that promotes generic market entry, the tension between the brand-name drug companies and the generic drug companies, and how this tension has played out in the actions and legal battles of three brand-name drug companies. It will also discuss recent legislation and rule changes that have sought to prevent the brand-name drug companies from “gaming” the system while leveling the playing field for generic drug companies. Recommendations are also made for further ways to improve the existing legal framework.